Multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette superfamily. Using the energy provided by ATP hydrolysis, it transports a broad spectrum of substrates across the plasma membrane, including hormones, leukotriene C 4 , bile salts, and anti-cancer drugs.
A major obstacle to chemotherapy is the emergence of a resistance to anti-cancer drugs associated to the overexpression in the plasma membrane of drug transporters. These proteins reject a broad spectrum of chemotherapeutic agents out of the cells and are responsible for the multidrug-resistant (MDR) phenotype in human cells. Most of these proteins belong to the ATP-binding cassette (ABC) superfamily and use the energy provided by ATP hydrolysis to export cytotoxic drugs outside the cells [1] .
P-glycoprotein (Pgp), the first discovered member of the ABC superfamily [2] , extrudes from the cell a wide variety of cytotoxic drugs. Recent works have suggested the association of Pgp to cholesterol and sphingolipid-rich membrane microdomains called detergent-resistant membranes (DRMs) [3, 4] . Inhibition of Pgp transport and ATPase activities by cholesterol-depleting agents like methyl-bcyclodextrin (MbCD) [5, 6] supports this view. Moreover, cholesterol upregulates Pgp ATPase activity and drug transport in proteoliposomes and cell systems [5, 7, 8] .
The main objective of the present work is to determine whether other ABC transporters are associated to cholesterol and sphingolipid-rich structures and whether cholesterol modulates their ATPase and transport activities. Multidrug resistance protein 1 (MRP1) is another protein belonging to this large superfamily of ABC proteins [1] . It transports a broad range of substrates across the plasma membrane [9] . It is an integral membrane protein made of three transmembrane domains (TMDs) and two cytosolic nucleotide-binding domains (NBDs) [1] . Drug binding sites are located into the transmembrane domains [10] .
Our experiments carried out on human embryonic kidney cells (HEK-293) overexpressing MRP1 revealed that MRP1 is not located in DRMs. After Triton X-100 extraction of DRMs, MRP1 did not co-localize with Flotillin-1, a known DRM marker protein [11] . Confocal microscopy experiments confirmed distinct localizations of MRP1 and GM1, a typical DRM ganglioside [12] . Experiments carried out on MRP1 proteoliposomes containing increasing amounts of cholesterol revealed that MRP1 drug transport and ATPase activity are downregulated by cholesterol.
Materials and methods

Materials. [
3 H]LTC 4 was purchased from Perkin-Elmer. Asolectin was from Avanti. LTC 4 , methyl-b-cyclodextrin and cholesterol were from Sigma-Aldrich. Antibodies: MRPm6 (Chemicon International), antiFlotillin-1 (BD Biosciences), Alexa Fluor 488 and cholera toxin Alexa Fluor 594 conjugate (Molecular Probes), anti-cholera toxin (Calbiochem).
Cell culture. Human embryonic kidney cell line (HEK-293), stably transfected to overexpress MRP1 (HEK-293-MRP1), were grown as adherent monolayer cultures in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL) supplemented with 10% foetal bovine serum (Gibco-BRL), 2% L-glutamine (Gibco-BRL), and 1% penicillin/streptomycin/fungizone (Gibco-BRL) at 37°C in a humidified atmosphere (99%) of 5% (v/v) CO 2 .
Triton X-100 extraction of DRMs. Extraction of DRMs was performed on HEK-293-MRP1 cells. Cells were washed three times in PBS buffer and resuspended in 1 ml ice-cold MNE buffer (MES 50 mM, pH 6.5; NaCl 150 mM; EDTA 5 mM; Triton X-100 1% (Sigma-Aldrich); anti-proteases (Complete, Roche): one tablet in 50 ml). After incubation (15 min at 4°C), homogenization with a potter (five times), and centrifugation (2 · 10 min, 5000 rpm), DRMs were mixed with an equal volume sucrose 80%, overlaid by a discontinuous sucrose gradient 30-5% and ultracentrifuged overnight. The gradient was fractionated and these fractions were run on a polyacrylamide SDS-PAGE gel 7.5% analysed by Western blot (antibodies: MRPm6 for MRP1 and anti-Flotillin-1 for DRMs).
Confocal microscopy. Confocal microscopy was performed on 5 · 10 5 HEK-293-MRP1 cells seeded in a 24-well plate on coverslips coated with polylysine. When the cells had grown to confluence, they were washed once in PBS containing 1% BSA for 10 min. Cells were incubated 30 min with the anti-GM1 cholera toxin (subunit B) Alexa Fluor 594 conjugate, washed 10 min and then incubated 30 min with anti-cholera toxin antibody. After 10 min washing, cells were fixed with 2% paraformaldehyde in PBS for 10 min, permeabilized in 0.1% Triton X-100 for 10 min and incubated 1 h with the anti-MRP1 MRPm6 antibody. After washing with the blocking solution for 10 min, cells were incubated with Alexa Fluor 488 anti-mouse IgG fragment for 1 h. Coverslips were mounted on the slides with one drop of antifade reagent (Calbiochem). Localizations of MRP1 and GM1 in the cells were determined with a laser scanning confocal microscope (MRC 1000; Bio-Rad, Hercules, CA) equipped with an argon-krypton laser and Comos software (Bio-Rad). Purification and reconstitution of MRP1. Purification and reconstitution of MRP1 were carried out as described previously [9] .
ATPase activity measurement. The ATPase activity of proteoliposomes was measured as described previously [9] .
Transport assays. Standard transport assays were carried out as described previously [13] .
Results and discussion
Is MRP1 associated to lipid raft-like structures? MRP1 and Pgp have been shown to transport the same substrates and their membrane topologies, if we except the amino-terminal end of MRP1, are quite similar. These features would suggest the insertion of MRP1 into DRMs. Western blot analysis of cell-extracted DRMs and confocal microscopy measurements were carried out to determine the localization of MRP1 in the plasma membrane.
Triton X-100 extraction of DRMs
A classical way to demonstrate the insertion of a protein in DRM structures is to isolate them from cells by a cold nonionic detergent. DRMs were extracted from HEK-293 cells overexpressing MRP1 by cold Triton X-100. The extracts were separated on a sucrose density gradient, which was fractionated after ultracentrifugation. The distribution of MRP1 and Flotillin-1, a DRM marker protein [11] , among the different fractions was analysed by Western blotting. MRP1 was not associated with the low-density fractions containing Flotillin-1 (fractions 9-12) ( Fig. 1 ) but was detected in fractions 1-6 representative of the Triton X-100-solubilized proteins. Some Flotillin-1 was also detected in these fractions indicating partial solubilization of some DRMs. DRMs migrate at the 30-5% sucrose interface of the gradient (Flotillin-1 was detected in fractions [9] [10] [11] [12] . No MRP1 was detectable in these fractions suggesting that MRP1 is not localized in DRMs.
Confocal fluorescence microscopy
The localization of MRP1 in the plasma membrane was investigated by confocal fluorescence microscopy on HEK-293-MRP1 cells. DRMs were detected by cholera toxin Fig. 1 . Sucrose density gradient partitioning MRP1 and marker of classical lipid rafts (Flotillin-1). HEK-293 cells were lysed in 1% (v/v) Triton X-100 at 4°C and lysates were fractionated by ultracentrifugation on a discontinuous sucrose gradient. A total of 14 fractions were collected and an aliquot of each was run on SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and MRP1 and Flotillin-1 were detected by Western immunoblot analysis.
(subunit B) Alexa Fluor 594 conjugate that targets GM1, a DRM component, and visualized by red fluorescence and MRP1 by MRPm6, a mouse MRP1-specific primary monoclonal antibody raised against a linear epitope located near the intracellular COOH-terminus of the protein. The anti-mouse secondary antibody Alexa Fluor 488 is visualized by green fluorescence. A yellow colour demonstrates the co-localization of the two proteins. As shown in Fig. 2A, MRP1 (green) does not co-localize with GM1 (red) as indicated by the absence of any yellow colour.
Cells were incubated with 10 mM methyl-b-cyclodextrin, a commonly used membrane cholesterol-depleting agent, for 30 min. The homogenous distribution of the red colour associated to GM1 in the cell membrane demonstrates that DRMs have been disrupted (Fig. 2B) . After cholesterol depletion, GM1 and MRP1 are randomly distributed as illustrated by the yellow colour resulting from the overlay of red and green fluorescences.
Does cholesterol affect MRP1 ATPase activity and MRP1-mediated drug transport and how?
The role of cholesterol was assessed in a reconstituted system that has been used previously [9, 13, 14] . Drug transport and ATPase activity of MRP1 have been shown to be retained in this reconstituted system [13] and the amount of cholesterol in the lipid membrane can be carefully controlled.
ATPase activity measurements
ATPase activity of MRP1 reconstituted in the absence of cholesterol was about 11 ± 1.3 nmol/mg/min and comparable with the ones reported previously for MRP1 (8 nmol/mg/min) by Manciu et al. [9] and 5-10 nmol/mg/ min by Mao et al. [15] ). However, MRP1 ATPase activity decreases by about 40% when reconstituted in proteoliposomes containing 20-40% cholesterol (molar ratio) (Fig. 3) . No significant change could be detected at 5%.
Transport assays
Proteoliposomes containing MRP1 and increasing amounts of cholesterol were incubated with [ 3 H]LTC 4 (150 nM, 100 nCi) and the uptake of LTC 4 into the proteoliposomes was determined in the presence of 4 mM MgATP or 4 mM MgAMP (Fig. 4) . Twenty percent cholesterol (molar ratio) significantly downregulated LTC 4 uptake. Uptake detected in the presence of MgAMP corresponded to passive diffusion and partitioning of LTC 4 into the lipid bilayer and does not depend on cholesterol concentration.
Pgp is associated to DRM structures [3, 4] whereas our DRM extraction from HEK-293-MRP1 cells with Triton X-100 revealed MRP1 in the high-density detergent-soluble fractions. These data are in agreement with those of Hinrichs et al., showing most of MRP1 in the Triton X-100-soluble fractions of MDR HT29 col human colon carcinoma [16] . However, MRP1 was almost completely localized in the Lubrol-insoluble fractions of HT29 col cells [16] . Therefore the results of DRMs extraction by cold nonionic detergent must be interpreted as a function of the detergent used for assaying their solubilization resistance. Radeva and Sharom indeed reported that the nonionic detergents Brij-96 and Triton X-100 isolated different DRMs microdomains [17] , which differ from their buoyant density, determined by the lipid and protein content [18] . This distribution also depends on the cell type. Pgp has been shown to exist in DRM and in non-DRM membrane domains as well, in proportions depending on the cell considered [19] . Moreover, the expression level of a protein can also influence its DRM localization. As previously demonstrated, the lower the Pgp expression level, the higher the Pgp fraction located in the low-density DRMs [20, 21] . To eliminate artefacts related to the protocol of DRMs extraction, we carried out confocal microscopy experiments that confirmed the absence of MRP1 in DRM structures.
It has been reported that cholesterol, one of the major DRMs components, modulates Pgp activity. Cholesterol addition to cholesterol-depleted human lymphocytes led to a marked decrease of rhodamine123 cellular uptake [22] . Human polarized Hep G2 cells were incubated with 0.2 mM methyl-b-cyclodextrin and then with cyclodextrin-cholesterol complexes to restore cholesterol to baseline levels. Under these conditions, daunomycin accumulation in cells was the same as in control cells. Interestingly, content of daunomycin in Hep G2 cells was lower than in control cells when cholesterol was replaced with its enantiomer, ent-cholesterol [20] . Depletion of cholesterol and replacement with ent-cholesterol suggested rather a direct specific cholesterol effect. Experiments also showed an upregulation of drug transport and ATPase activity of Pgp with the cholesterol content [19] . On the opposite, our data demonstrate that incorporation of up to 30% of cholesterol in MRP1 proteoliposomes downregulated both the ATPase and the transport activities of reconstituted MRP1. Dijkhuis et al. made a similar observation on human neuroblastoma cell lines expressing MRP1 and Pgp. They showed that ganglioside depletion had a slightly stimulatory effect on MRP1 transport activity and on the contrary, an inhibitory effect on Pgp [23] . Whatever the changes that have occurred in the lipid bilayer organization as a consequence of the increase of cholesterol content, it is likely that they are transmitted from the transmembrane domains to the nucleotide-binding domains involved in ATP binding and hydrolysis. Such a transmission of conformational changes occurring in distinct domains of MRP1 has been described previously [9] .
Cholesterol can influence membrane protein activity either by rigidifying the environment of the protein or by direct interaction with the protein. It is known that cholesterol enhances the microviscosity of the lipid bilayer in asolectin liposomes [24, 25] . However, even if experiments were carried out in MRP1 and Pgp proteoliposomes characterized by the same microviscosity, one cannot exclude that both MRP1 and Pgp require a specific lipid microviscosity to optimize their transport and ATPase activities. On the other hand, preliminary experiments carried out in our group suggest that cholesterol and ent-cholesterol affect differently the accessibility of MRP1 to the aqueous medium although they are known to affect similarly the physical membrane properties, including membrane microviscosity [26] . At this stage, we cannot decide whether the effect of cholesterol on MRP1 ATPase and transport activities is related to a direct interaction of MRP1 with cholesterol or to an indirect effect due to the cholesterol-induced modification of the membrane microviscosity.
Why does MRP1 seem to avoid cholesterol-rich membrane microdomains while Pgp [3, 4] and CFTR [27] do not? Actually, predicting how a membrane protein will partition into distinct membrane microdomains on the basis of the protein structure is not possible. Nevertheless, certain structural features could favour interaction of the protein with cholesterol-rich membrane microdomains. For exam- ple, certain types of lipidations found in proteins, favour the association with DRMs. The nature of the transmembrane domains of the protein could also be important. Moreover, several proteins contain a juxtamembrane segment that can interact with cholesterol [28] . One is the CRAC sequence (cholesterol recognition/interaction amino acid consensus) present at the end of a transmembrane helix [29] and the other cholesterol-binding motif is the sterol sensing domain (SSD) made of five transmembrane helices [30] , which can contain the sequence YIYF having considerable potency to bind cholesterol [28] . MRP2, believed to sequester to DRMs [31, 32] , contains a YLFF sequence in a similar position to the YIYF of MRP3 [28] . We did not identify such a sequence in MRP1. Interestingly, the distribution of Pgp and MRP1 in DRM and non-DRM structures is in agreement with their distribution in polarized cells. MRP1 expressed in polarized pig kidney epithelial cell line is mainly localized to the basolateral plasma membrane of these cells and not to the apical membrane, as determined by immunocytochemistry using confocal laser scanning and electron microscopy [33] . On the opposite, Pgp is mainly localized to apical membrane of polarized epithelial cells [34] , which is enriched in sphingolipids and cholesterol as compared with basolateral surface [35] .
Several substrates are transported by both MRP1 and Pgp but with different efficiencies. Such a difference might be related to the much higher ATPase activity of Pgp as compared to that of MRP1 [36] . During acquisition of the multidrug-resistant phenotype, MRP1 and Pgp can be overexpressed together in some cell types. It is likely that MRP1 would be preferentially overexpressed at low concentrations of the chemotherapeutic agent. On the contrary, Pgp, which have a higher ATPase activity, would transport the same substrates as MRP1 but at higher concentrations of the drug [37] .
